Recent Pathophysiological Aspects of Peyronie’s Disease: Role of Free Radicals, Rationale, and Therapeutic Implications for Antioxidant Treatment-Literature Review
Open accessThe DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Abstract
Peyronie’s disease (PD) is a chronic inflammation of tunica albuginea of the corpora cavernosa that causes an inelastic plaque resulting in penis deformation. Although its etiology is not completely known, there is general consensus that PD is genetically transmitted and secondary to penile trauma. In recent years, numerous studies demonstrated the role played by oxidative stress in PD pathogenesis, and other studies have described successful use of antioxidants in PD treatment. Oxidative stress is an integral part of this disease, influencing its progression. In the early stages of PD, the inflammatory infiltrate cells produce high quantities of free radicals and proinflammatory and profibrotic cytokines, with consequent activation of transcription factor NF- κ B. While conservative therapies commonly used in the early stages of PD include oral substances (Potaba, tamoxifen, colchicine, and vitamin E), intralesional treatment (verapamil, interferon, steroids, and more recently collagenase clostridium histolyticum-Xiaflex), and local physical treatment (iontophoresis, extracorporeal shock wave therapy, and penile extender), the significant results obtained by emerging treatments with the antioxidants cited in this article suggest these therapeutic agents interfere at several levels with the disease’s pathogenetic mechanisms. Antioxidants therapy outcomes are interesting for good clinical practice and also confirm the fundamental role played by oxidative stress in PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“PD progresses in two main stages. The first phase typically lasts between 12 and 18 months; this phase is the “active inflammatory phase”, in which plaque forms and progresses to fibrosis and potential calcification, accompanied by pain and worsening of the penile deformity. In the second phase, known as the chronic “stabilized phase”, penile pain decreases and the plaque size and deformity stabil”
From Clinical Presentation of Peyronie’s Disease: A Retrospective Study of 564 Cases (2024) · cites this paper as [21]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Activated NF-κB has been observed in penile tissues affected by PD, suggesting its involvement in the inflammatory response.”
From Research advances in Peyronie's disease: a comprehensive review on genomics, pathways, phenotypic manifestation, and therapeutic targets. (2024) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current drugs such as collagenase Clostridium histolyticum, exemplified by Xiaflex, is a proteolytic enzyme that selectively targets and breaks down collagen, specifically within fibrous plaques.63,139”
From Research advances in Peyronie's disease: a comprehensive review on genomics, pathways, phenotypic manifestation, and therapeutic targets. (2024) · cites this paper as [63]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the scientific literature, several articles have appeared in the 21st century that have clarified the important role that “oxidative stress” plays in the pathophysiology of PD [15,16,17,18,19,20,21,22].”
From Clinical Presentation of Peyronie’s Disease: A Retrospective Study of 564 Cases (2024) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vascular endothelial cells synthesize nitric oxide from L-arginine
Palmer, R. M. J., Ashton, D. S., & Moncada, S. (1988) · Nature · doi:10.1038/333664a0 · Cited by 4,769 · cited 2×
“The chemical process requires molecular oxygen and proceeds via synthesis of an intermediate, N𝜔hydroxyarginine [46].”
BackgroundHealth effects of quercetin: From antioxidant to nutraceutical
Boots, A. W., Haenen, G. R. M. M., & Bast, A. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.03.008 · Cited by 2,121 · cited 1×
“It is able to scavenge highly reactive species such as peroxynitrite, hydroxyl radical, superoxide anion, singlet oxygen, and lipid peroxyl radicals [106].”
BackgroundAntioxidant and antiradical activities of l-carnitine
Gülçin, İ. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.05.103 · Cited by 993 · cited 1×
“It is scavenger and neutralizer of superoxide anion, hydrogen peroxide, and peroxynitrite [64].”
BackgroundAntioxidant activity of propolis of various geographic origins
Kumazawa, S., Hamasaka, T., & Nakayama, T. (2004) · Food Chemistry · doi:10.1016/s0308-8146(03)00216-4 · Cited by 946 · cited 1×
“Less than 10mg/g of CAPE is found instead in propolis extracts from Argentina, Bulgaria, Chile, Ukraine, and USA [99].”
BackgroundRecent advances in the chemical composition of propolis
Huang, S., Zhang, C.-P., Wang, K., Li, G., & Hu, F.-L. (2014) · Molecules · doi:10.3390/molecules191219610 · Cited by 765 · cited 1×
“Poplars, and their buds in particular, are considered themain indirect source of propolis in Europe and North America, nontropical Asia, New Zealand, and North Africa (especially the Nile delta) [100].”
BackgroundCarnitine biosynthesis in mammals
Vaz, F. M., & Wanders, R. J. A. (2002) · Biochemical Journal · doi:10.1042/0264-6021:3610417 · Cited by 764
Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations.
Frei, B., Kim, M. C., & Ames, B. N. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.12.4879 · Cited by 620 · cited 1×
“In its reduced form, CoQ10 acts as a potent endogenous antioxidant, interacting with oxygen-related radicals, hydrogen peroxide, and singlet oxygen and inhibiting lipid peroxidation (Table 1) [90].”
BackgroundLambert, E., Dassé, E., Haye, B., & Petitfrère, E. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2003.09.008 · Cited by 541 · cited 2×
“This typically profibrotic growth factor is mainly produced by fibroblasts and myofibroblasts; it attracts fibroblasts in the area and induces their proliferation, stimulates collagen synthesis, increases synthesis of MMP-1 and MMP-9 (with elastic activity) and TIMP-1, and causes further local fibrin deposit [6, 33, 3…”
BackgroundRaso, G. M., Meli, R., Di Carlo, G., Pacilio, M., & Di Carlo, R. (2001) · Life Sciences · doi:10.1016/s0024-3205(00)00999-1 · Cited by 448 · cited 1×
“Moreover quercetin inhibits inflammatory enzymes cyclooxygenase (COX), lipoxygenase (LOX), and iNOS [108].”
BackgroundThe prevalence of Peyronie's disease: results of a large survey
Schwarzer, U., Sommer, F., Klotz, T., Braun, M., Reifenrath, B., & Engelmann, U. (2001) · BJU International · doi:10.1046/j.1464-4096.2001.02436.x · Cited by 440 · cited 1×
“2% and 13%; it generally affects males around 50 years of age, but recently a rise in frequency has been recorded in younger patients [1, 2].”
Background
Research works printed but not linked: 19
- 1989, Journal of Urology, 141, 629
- 2015, Diagnosis and management of peyronie disease, 1, chap 31, 722
- 1993, Journal of Periodontology, 64, 450
- 2007, The clinical implications of basic science research in Peyronies disease, a guide to clinical management, 39
- 1994, Lymphokine and Cytokine Research, 13, 309
- 2011, Journal of the Medical Association of Thailand, 94
- 1996, Cancer Epidemiol Biomarkers Prev, 5, 263
- 1983, Prog Reprod Biol Med, 9, 41
- 2012, Journal of medicine and life, 5, 192
- 2004, Annals of Clinical & Laboratory Science, 4, 427
- 1995, Journal of Rheumatology, 22, 595
- 2006, Asian Pacific Journal of Cancer Prevention, 7, 22
- 1998, Archivos Españoles de Urología, 51, 171
- 2003, Archivos Espanoles de Urologia, 56, 805
- 2003, Archivos Espanoles de Urologia, 56, 814
- 2005, Archivos Espanoles de Urologia, 58, 931
- 2007, Medicina (Kaunas, Lithuania), 43, 971
- 1990, The Main Phenolics of Fruit, 1
- 2007, NUTRAfoods, 6, 13
Cited by
A review of inflammation and fibrosis: implications for the pathogenesis of Peyronie’s disease
Patel, D. P., Christensen, M. B., Hotaling, J. M., & Pastuszak, A. W. (2020) · World Journal of Urology · doi:10.1007/s00345-019-02815-6 · Cited by 64
Mia, M. M., & Bank, R. A. (2015) · Cell and Tissue Research · doi:10.1007/s00441-015-2285-6 · Cited by 33
Paulis, G., & Berardesca, E. (2019) · Research and Reports in Urology · doi:10.2147/rru.s205184 · Cited by 38
Self-citationMolecular Mechanisms and Current Pharmacotherapy of Peyronie’s Disease: A Review
Zhang, F., Qin, F., & Yuan, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.643641 · Cited by 29
“Although the mechanisms of PD are not fully understood several molecular pathological changes of the PD plaque have been recognized recently (Graziottin, 2015; Paulis et al., 2017).”
BackgroundGelbard, M. K., & Rosenbloom, J. (2021) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.195 · Cited by 24
Paulis, G., De Giorgio, G., & Paulis, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415969 · Cited by 21
“Instead of being reabsorbed (as occurs in males who are not genetically susceptible to the disease), the hematoma leads to the recruitment of inflammatory cells and proinflammatory cytokines, which inevitably results in the formation of chronic inflammatory tissue that evolves towards fibrosis [20,21].”
BackgroundSelf-citationContemporary surgical and non-surgical management of Peyronie’s disease
Wayne, G. F., & Cordon, B. H. (2018) · Translational Andrology and Urology · doi:10.21037/tau.2018.04.06 · Cited by 20
“Immunologic factors—autoimmune disease, HLA-B27 association, as well as relevant genes—OSF-1 (involved in osteoblast recruitment), MCP-1 (in macrophage recruitment), procollagenase 4—have been implicated and may one day be pharmaceutical targets or agents for diagnosis (8-10).”
BackgroundChi, J., Bi, W., Lou, K., Ma, J., Wu, J., & Cui, Y. (2024) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qeae006 · Cited by 14
Minimally invasive therapies for Peyronie’s disease: the current state of the art
Farrell, M. R., Ziegelmann, M. J., & Levine, L. A. (2020) · Translational Andrology and Urology · doi:10.21037/tau.2019.08.06 · Cited by 14
“It is also becoming increasingly clear that oxidative stress, including the presence of reactive oxygen species, plays a role in the pathogenesis of PD as well (13,14).”
BackgroundPiraino, J., Chaudhary, H. T., Ames, K., Okoye, F., Sterling, M. E., Clavell-Hernández, J., Levine, L. A., & Ziegelmann, M. J. (2022) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2022.08.001 · Cited by 16
Peyronie’s Disease: An Outcomes-Based Guide to Non-Surgical and Novel Treatment Modalities
Reddy, A. G., Dai, M., Song, J. J., Pierce, H. M., Patel, S. R., & Lipshultz, L. I. (2023) · Research and Reports in Urology · doi:10.2147/rru.s278796 · Cited by 19
“Production of the above inflammatory factors and ROS additionally promotes NF-κB activation, propagating further release of inflammatory cytokines.(18) Platelet-derived growth factor (PDGF) has also been implicated in ECM deposition and fibrotic plaque formation.”
Clinical Presentation of Peyronie’s Disease: A Retrospective Study of 564 Cases
Paulis, G., De Giorgio, G., & Paulis, A. (2024) · Diagnostics · doi:10.3390/diagnostics14111125 · Cited by 11
“In the second phase, known as the chronic “stabilized phase”, penile pain decreases and the plaque size and deformity stabilize [2,15,19,21,22,30,31].”
BackgroundSelf-citationPaulis, G., & Giorgio, G. D. (2022) · Antioxidants · doi:10.3390/antiox11091661 · Cited by 11
“Pentoxifylline has the following action properties: the inhibition of ROS and lipid oxidation; the inhibition of myofibroblastic differentiation of fibroblasts; a reduction in collagen deposition; NFK-B factor inhibition; proinflammatory cytokine-expression inhibition; COX-2 inhibition; TGF-beta-1 inhibition; PAI 1-ex…”
BackgroundSelf-citationPaulis, G., & Giorgio, G. D. (2022) · American Journal of Case Reports · doi:10.12659/ajcr.936146 · Cited by 10
“All the substances we used in the combined therapy (propolis, bilberry, coenzyme Q10, silymarin, ginkgo biloba, vitamin E, L-carnitine, and diclofenac) inhibit activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and block the production of pro-inflammatory cytokines [8].”
BackgroundSelf-citationYang, X., Wu, J., Cai, T., Shan, J., & Cui, Y. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111286 · Cited by 9
Ultrasound Elastography as a Diagnostic Tool for Peyronie’s Disease: A State-of-the-Art Review
Paulis, G., Giorgio, G. D., & Paulis, A. (2024) · Diagnostics · doi:10.3390/diagnostics14060665 · Cited by 10
Self-citationNoninvasive Treatment Options for Peyronie’s Disease
Ory, J., MacDonald, L., & Langille, G. M. (2020) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2019.12.002 · Cited by 9
Paulis, G., & Giorgio, G. D. (2022) · Journal of Medical Case Reports · doi:10.1186/s13256-022-03614-1 · Cited by 9
Self-citationPaulis, G., Paulis, A., Giorgio, G. D., & Quattrocchi, S. (2024) · Metabolites · doi:10.3390/metabo14010055 · Cited by 8
Self-citationMoghalu, O. I., Das, R., Horns, J. J., Campbell, A., Hotaling, J. M., & Pastuszak, A. W. (2021) · International Journal of Impotence Research · doi:10.1038/s41443-021-00430-x · Cited by 7
Peyronie Disease as a Marker of Inflammation—Is There Hope on the Horizon?
Swislocki, A., & Eisenberg, M. L. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.06.015 · Cited by 8
Bolgeo, T., Matteo, R. D., Gardalini, M., Gatti, D., Maconi, A., & Boccafoschi, C. (2022) · Archivio Italiano di Urologia e Andrologia · doi:10.4081/aiua.2022.1.75 · Cited by 7
Paulis, G., & Giorgio, G. D. (2022) · Clinics and Practice · doi:10.3390/clinpract12060105 · Cited by 5
“Oxidative stress, in particular, was recently found to be crucial to plaque formation and the evolution of PD itself [13,14].”
BackgroundSelf-citationPaulis, G., & Paulis, A. (2025) · Antioxidants · doi:10.3390/antiox14020208 · Cited by 6
“RNS play a role in promoting a higher oxidation state (nitro-oxidation), which leads to lipid peroxidation, DNA fragmentation, protein nitration, and vasoconstriction [21,22,49,52–54].”
InfluentialSelf-citationIs high levels of vitamin D a new risk factor for Peyronie's disease?
Canat, H. L., Can, O., Özbir, S., Çakır, S. S., Çulha, M. G., Bayraktarlı, R. Y., & Atalay, H. A. (2019) · Andrologia · doi:10.1111/and.13368 · Cited by 5
Ilg, M. M., Ralph, D. J., & Cellek, S. (2023) · The Journal of Sexual Medicine · doi:10.1093/jsxmed/qdad051 · Cited by 5
Paulis, G., Pisano, F., Palmieri, A., Cai, T., Palumbo, F., & Giammusso, B. (2021) · Archivio Italiano di Urologia e Andrologia · doi:10.4081/aiua.2021.3.348 · Cited by 3
“Supposedly, fibrin accumulation then causes recruitment of inflammatory cells (neutrophils and macrophages), with consequent overproduction of pro-inflammatory fibrogenic cytokines and reactive oxygen species (ROS) (7-12).”
BackgroundSelf-citationTienforti, D., Hoxha, M., Pasquale, A. B. D., Rizza, V., & Barbonetti, A. (2024) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qeae038 · Cited by 2
Paulis, G., Giorgio, G. D., & Paulis, A. (2024) · Archivio Italiano di Urologia e Andrologia · doi:10.4081/aiua.2024.12690 · Cited by 2
Self-citationUnraveling the Complexity of Peyronie's Disease: A Comprehensive Exploration
Romero, A. R., Rosas, J. M. P., Maya, G. M., Jiménez, A. L., Hernández, D. I. R., & Ledezma, A. G. (2023) · International Journal of Medical Science and Clinical Research Studies · doi:10.47191/ijmscrs/v3-i12-45 · Cited by 2
Measurement of Oxidative Stress Index in 102 Patients with Peyronie’s Disease
Paulis, G., Paulis, A., Giorgio, G. D., & Quattrocchi, S. (2025) · Metabolites · doi:10.3390/metabo15080503 · Cited by 3
“The first stage corresponds to the initial phase (active phase), which lasts for about 12–18 months, during which plaque formation and growth occur [19].”
Self-citationThe psychological impact of Peyronie's disease: a retrospective analysis of 603 patients
Paulis, G., & Paulis, A. (2026) · Archivio Italiano di Urologia e Andrologia · doi:10.4081/aiua.2026.14758 · Cited by 1
Self-citationAdvancing Diabetic Wound Care: Topical Transferosomal Insulin Delivery for Improved Healing
Bhakuni, A., Singh, L., Gulia, M., Singh, R. P., Kumar, A., & Jhawat, V. (2026) · Current Protein and Peptide Science · doi:10.2174/0113892037434672251121095324 · Cited by 1
Increasing effectiveness of conservative treatment of Peyronie’s disease
Жуков, О. Б., Vasilyev, A. E., & Novikov, M. Е. (2018) · Andrology and Genital Surgery · doi:10.17650/2070-9781-2018-19-4-78-84 · Cited by 1
“Кроме того, воспалительные клетки продуцируют эластазу, в присутствии которой происходит деградация эластических волокон белочной оболочки [7, 8].”
Could coenzyme Q10 be the treatment for Dupuytren’s disease?
Lourens, W. (2019) · BMJ Case Reports · doi:10.1136/bcr-2018-226419 · Cited by 1
Çakır, S. S., Özbir, S., Atalay, H. A., Çulha, M. G., Can, O., & Canat, H. L. (2019) · The World Journal of Men s Health · doi:10.5534/wjmh.190039
“org fibrin and platelets accumulate between the layers of the penis due to extravasation [5].”
BackgroundPeyronie’s disease: Review of the pathology and current events in treatment
Carrillo-Córdova, L. D., Rodríguez-Valle, E. D., Rodríguez-Robles, J. A., Vitar-Sandoval, J., Calvo-Mena, D., Garduño-Segovia, N., Aguilar-Aizcorbe, S., Reyes-Sánchez, A., Acevedo-García, C., Jaspersen-Gastelum, J. A., et al. (2019) · Revista Médica Del Hospital General De México · doi:10.24875/hgmx.m19000017
Oral therapy and anti-oxidants
Corona, G., Bianchi, N., Prontera, O., Dicuio, M., Sforza, A., & Maggi, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819468-3.00010-0
Understanding the Pathological Stages of Peyronie’s Disease and Treatment Options at Each Stage
Emara, S. (2020) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2020.30.005004
“Oral Therapy Vitamin E: Studies on the use of vitamin E in Peyronie’s disease have shown a decrease in penile curvature in 78% of patients and a decrease in plaque size in 91%[25].”
BackgroundWas tun bei Induratio penis plastica?
Christoph, F., & Schrader, M. G. (2023) · Uro-News · doi:10.1007/s00092-023-5854-0
Braga, C. D. M., & Cantilino, A. (2024) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qeae002
Alzahrani, A. M., Aleid, M., Yin, A., Alshamsi, H., Sioufi, J., Aubé-Peterkin, M., & Carrier, S. (2026) · Research Square · doi:10.21203/rs.3.rs-10029540/v1
Dikici, İ. H., Salar, R., Öncel, H. F., & Taşkın, S. (2026) · Andrology · doi:10.1111/andr.70343
Fernández‐Pascual, E., Maiolino, G., Hendges, L. P. P., de la Morena, C. S., Solano-Heranz, P., Martínez‐Piñeiro, L., Lledó-García, E., & Martínez‐Salamanca, J. I. (2026) · The Journal of Sexual Medicine · doi:10.1093/jsxmed/qdag278
Metadata
- Authors
- Paulis, G., Romano, G., Paulis, L., & Barletta, D.
- Affiliations
- Ospedale Regina Apostolorum (IT)
- Italian League against Cancer, Department of Urologic Oncology, Section of Avellino, Avellino, Italy
- Sapienza University of Rome (IT)
- Policlinico San Matteo Fondazione (IT)
- Corresponding author
- Paulis, Gianni
- ORCID
- Paulis, Gianni
- Venue
- Advances in Urology
- Publisher
- Wiley
- Published
- 2017
- Volume
- 2017
- Pages
- 1-17
- ISSN
- 1687-6369 (ISSN-L)
- 1687-6377
- PMC
- PMC5514334
- OpenAlex
- W2730490361
- Cited by
- 44
- References
- 144
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 8 · 2023: 4 · 2022: 7 · 2021: 4 · 2020: 5 · 2019: 6 · 2018: 2
- FWCI
- 0.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Advances in Urology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Rheumatology › Dupuytren's Contracture and Treatments
- Health Sciences › Medicine › Urology › Urological Disorders and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Keywords
- Peyronie's disease, oxidative stress, free radicals, antioxidants, tunica albuginea, penile plaque, NF-κB, inflammatory cytokines, collagenase clostridium histolyticum, intralesional therapy, extracorporeal shock wave therapy, iontophoresis, tamoxifen, colchicine, vitamin E, verapamil, interferon, penile trauma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
